Three-year clinical course after fluoropolymer-based drug-eluting stent implantation for femoropopliteal lesions
BACKGROUND: Although the 1-year clinical outcomes of fluoropolymer-based drug-eluting stents (FP-DES) were favorable for the treatment of real-world femoropopliteal lesions in symptomatic peripheral artery disease (PAD), their performance beyond 1 year remained unknown. The current study determined the 3-year clinical course of FP-DES implantation for real-world femoropopliteal lesions.
METHODS: This multicenter, prospective, observational study evaluated 1204 limbs (chronic limb-threatening ischemia, 34.8%; mean lesion length, 18.6 ± 9.9 cm, chronic total occlusion: 53.2%) of 1097 patients with PAD (age, 75 ± 9 years; diabetes mellitus, 60.8%) undergoing FP-DES implantation for femoropopliteal lesions. The primary outcome measure was 3-year restenosis. The secondary outcome measures included 3-year occlusive restenosis, stent thrombosis, target lesion revascularization (TLR), and aneurysmal degeneration.
RESULTS: The 3-year cumulative occurrence of restenosis was 27.3%, whereas that of occlusive restenosis, stent thrombosis, and TLR was 16.1%, 7.3%, and 19.6%, respectively. The annual occurrence of restenosis decreased by 12.0%, 9.5%, and 5.8% in the first, second, and third year, respectively (p < 0.001). Similarly, the rates of occlusive restenosis and stent thrombosis decreased (p < 0.001 and p = 0.007, respectively), whereas the rate of TLR remained unchanged for 3 years (p = 0.15). The incidence of aneurysmal degeneration at 3 years (15.7%) did not significantly differ from that at 1 and 2 years (p = 0.69 and 0.20, respectively).
CONCLUSIONS: This study highlights the favorable long-term clinical course of FP-DES in real-world practice, emphasizing the importance of monitoring for occlusive restenosis and stent thrombosis while considering the potential onset of aneurysmal degeneration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Vascular medicine (London, England) - 29(2024), 2 vom: 01. Apr., Seite 182-188 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Iida, Osamu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Endovascular therapy |
|---|
| Anmerkungen: |
Date Completed 12.04.2024 Date Revised 29.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1358863X241228261 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369468724 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369468724 | ||
| 003 | DE-627 | ||
| 005 | 20240429232041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1358863X241228261 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1392.xml |
| 035 | |a (DE-627)NLM369468724 | ||
| 035 | |a (NLM)38457137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Iida, Osamu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Three-year clinical course after fluoropolymer-based drug-eluting stent implantation for femoropopliteal lesions |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2024 | ||
| 500 | |a Date Revised 29.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Although the 1-year clinical outcomes of fluoropolymer-based drug-eluting stents (FP-DES) were favorable for the treatment of real-world femoropopliteal lesions in symptomatic peripheral artery disease (PAD), their performance beyond 1 year remained unknown. The current study determined the 3-year clinical course of FP-DES implantation for real-world femoropopliteal lesions | ||
| 520 | |a METHODS: This multicenter, prospective, observational study evaluated 1204 limbs (chronic limb-threatening ischemia, 34.8%; mean lesion length, 18.6 ± 9.9 cm, chronic total occlusion: 53.2%) of 1097 patients with PAD (age, 75 ± 9 years; diabetes mellitus, 60.8%) undergoing FP-DES implantation for femoropopliteal lesions. The primary outcome measure was 3-year restenosis. The secondary outcome measures included 3-year occlusive restenosis, stent thrombosis, target lesion revascularization (TLR), and aneurysmal degeneration | ||
| 520 | |a RESULTS: The 3-year cumulative occurrence of restenosis was 27.3%, whereas that of occlusive restenosis, stent thrombosis, and TLR was 16.1%, 7.3%, and 19.6%, respectively. The annual occurrence of restenosis decreased by 12.0%, 9.5%, and 5.8% in the first, second, and third year, respectively (p < 0.001). Similarly, the rates of occlusive restenosis and stent thrombosis decreased (p < 0.001 and p = 0.007, respectively), whereas the rate of TLR remained unchanged for 3 years (p = 0.15). The incidence of aneurysmal degeneration at 3 years (15.7%) did not significantly differ from that at 1 and 2 years (p = 0.69 and 0.20, respectively) | ||
| 520 | |a CONCLUSIONS: This study highlights the favorable long-term clinical course of FP-DES in real-world practice, emphasizing the importance of monitoring for occlusive restenosis and stent thrombosis while considering the potential onset of aneurysmal degeneration | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a endovascular therapy | |
| 650 | 4 | |a peripheral artery disease (PAD) | |
| 650 | 4 | |a vascular stent | |
| 650 | 7 | |a Fluorocarbon Polymers |2 NLM | |
| 700 | 1 | |a Takahara, Mitsuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Soga, Yoshimitsu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaoka, Terutoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujihara, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kawasaki, Daizo |e verfasserin |4 aut | |
| 700 | 1 | |a Ichihashi, Shigeo |e verfasserin |4 aut | |
| 700 | 1 | |a Sakata, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Mano, Toshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, Yoshiharu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vascular medicine (London, England) |d 1996 |g 29(2024), 2 vom: 01. Apr., Seite 182-188 |w (DE-627)NLM094881766 |x 1477-0377 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:2 |g day:01 |g month:04 |g pages:182-188 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1358863X241228261 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 2 |b 01 |c 04 |h 182-188 | ||